CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Urolithin A Hijacks ERK1/2-ULK1 Cascade to Improve CD8(+) T Cell Fitness for Antitumor Immunity.
Urolithin A Hijacks ERK1/2-ULK1 Cascade to Improve CD8(+) T Cell Fitness for Antitumor Immunity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
根据最新证据,微生物代谢产物尿石素A(UA)因其促进细胞健康的作用而闻名,可调节CD8+ T细胞介导的抗肿瘤活性。然而,UA的直接靶蛋白及其潜在机制仍不清楚。在此,本研究发现ERK1/2是UA介导CD8+ T细胞活化所必需的特异性靶点。即使在低剂量下,UA在体外和体内均显著增强原代CD8+细胞毒性T淋巴细胞(CTLs)和人嵌合抗原受体(CAR)T细胞的持久性和效应功能。在机制上,UA直接与ERK1/2激酶相互作用,增强其活化,随后通过参与ULK1促进T细胞活化。UA-ERK1/2-ULK1轴促进CD8+ CTLs中的自噬流,增强细胞代谢并维持活性氧(ROS)水平,表现为耗氧量和细胞外酸化率增加。经UA处理的CD8+ CTLs还显示ATP水平升高和备用呼吸能力增强。总体而言,UA激活ERK1/2,诱导自噬和代谢适应,展示了其在肿瘤免疫治疗和涉及ERKs的疾病干预中的潜力。
According to the latest evidence, the microbial metabolite Urolithin A (UA), known for its role in promoting cellular health, modulates CD8 + T cell-mediated antitumor activity.
However, the direct target protein of UA and its underlying mechanism remains unclear.
Here, this research identifies ERK1/2 as the specific target crucial for UA-mediated CD8 + T cell activation. Even at low doses, UA markedly enhances the persistence and effector functions of primary CD8 + cytotoxic T lymphocytes (CTLs) and human chimeric antigen receptor (CAR) T cells both in vitro and in vivo.
Mechanistically, UA interacts directly with ERK1/2 kinases, enhancing their activation and subsequently facilitating T cell activation by engaging ULK1. The UA-ERK1/2-ULK1 axis promotes autophagic flux in CD8 + CTLs, enhancing cellular metabolism and maintaining reactive oxygen species (ROS) levels, as evidenced by increased oxygen consumption and extracellular acidification rates. UA-treated CD8 + CTLs also display elevated ATP levels and enhanced spare respiratory capacity.
Overall, UA activates ERK1/2, inducing autophagy and metabolic adaptation, showcasing its potential in tumor immunotherapy and interventions for diseases involving ERKs.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。